Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand.



  • Client since 2017
  • AIM listed company providing specialist pharmacovigilance and CRO services to the global pharmaceutical industry


Consilium’s Strategy

  • Ongoing strategic advice and positioning of investment case as a full services business, amplification of significant news flow including multiple deals:
    • Acquisition of ADAMAS in February 2022
    • Provision of services to multiple COVID-19 trials
    • Acquisition of MedSource in December 2020
  • Strategic work for financial reporting and M&A and increasing awareness and visibility across business and investor media and retail investors



  • Successfully positioned investment case across all communications
  • Relationships strengthened across media with high quality and strategically-placed coverage
  • Increased awareness and understanding of business in the City amongst analysts and investors
  • Strengthened retail investor awareness of the company at investor event webinars